Vise Technologies Inc. Makes New Investment in Doximity, Inc. $DOCS

Vise Technologies Inc. acquired a new position in shares of Doximity, Inc. (NYSE:DOCS) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 18,426 shares of the company’s stock, valued at approximately $522,000.

Other institutional investors have also added to or reduced their stakes in the company. Avestar Capital LLC raised its stake in shares of Doximity by 122.6% in the 3rd quarter. Avestar Capital LLC now owns 23,034 shares of the company’s stock valued at $653,000 after buying an additional 12,688 shares in the last quarter. Signaturefd LLC grew its holdings in Doximity by 10.4% during the 3rd quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock worth $119,000 after acquiring an additional 397 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Doximity in the third quarter valued at approximately $611,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Doximity in the 3rd quarter valued at $251,000. Finally, Quadrant Capital Group LLC acquired a new stake in Doximity in the third quarter worth about $207,000. 87.19% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Phoebe Yang sold 1,290 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the sale, the director owned 24,744 shares of the company’s stock, valued at approximately $660,912.24. This represents a 4.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Timothy Cabral sold 10,721 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $375,235.00. Following the completion of the sale, the director owned 8,084 shares of the company’s stock, valued at approximately $282,940. This represents a 57.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 22,701 shares of company stock worth $717,401. 31.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DOCS. Raymond James Financial reissued an “outperform” rating and set a $38.00 price target on shares of Doximity in a research note on Friday, October 16th. JPMorgan Chase & Co. raised their target price on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Freedom Capital downgraded shares of Doximity from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Needham & Company LLC restated a “buy” rating and set a $41.00 price objective on shares of Doximity in a report on Friday, November 6th. Finally, Piper Sandler reissued an “overweight” rating and set a $47.00 price target (up from $42.00) on shares of Doximity in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.59.

More Doximity News

Investors following DOCS have been watching these news items:

• Positive Sentiment: Doximity rolled out DoseCheck, a product highlighted in connection with near-zero drug-dosing errors. The launch could add value to its clinical workflow offerings, although the report provided no revenue outlook or adoption figures. Article: Doximity Rolls Out DoseCheck
• Neutral Sentiment: Barclays raised its price target from $27 to $30 but kept an “equal weight” rating. The higher target is a modest positive, though it remains below the $33.34 price cited in the supplied market data, signaling limited upside at that level. Article: Barclays price target
• Negative Sentiment: Several law firms reiterated a securities class action and the November 16 lead-plaintiff deadline. The suit alleges Doximity misled investors about Newsfeed engagement, competition, advertising formats and revenue performance; these claims are allegations, not proven findings. The litigation may sustain uncertainty and reputational risk. Article: Doximity class-action reminder

Doximity Stock Performance

NYSE:DOCS opened at $33.34 on Thursday. The stock has a 50-day simple moving average of $29.47 and a 200 day simple moving average of $25.40. Doximity, Inc. has a 52-week low of $17.15 and a 52-week high of $53.46. The company has a market cap of $5.94 billion, a PE ratio of 42.10, a PEG ratio of 33.78 and a beta of 1.29.

Doximity (NYSE:DOCS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.17. The company had revenue of $174.54 million during the quarter. Doximity had a net margin of 21.12% and a return on equity of 15.80%. Doximity’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.45 earnings per share. On average, research analysts predict that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

Doximity Company Profile

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.